Navin Fluorine International Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Mixed quarter, H2 recovery thesis intact: Revenue grew 7% YoY despite a 30% drop in Specialty and 13% drop in CDMO, as HPP surged 66%. Management reiterated that the second half will be better than the first, with improving margins.
• Agchem destocking is the main drag, not structural loss: Global agro majors are deferring purchases to rationalize inventory, not shifting share to China. The company's innovator-heavy portfolio and cost-based contracts protect margins, and demand is expected to begin recovering from late Q2.
• CDMO pipeline is advancing, but revenue is lumpy: A UK major pharma program moved from development to scale-up, a European player completed pre-validation, and a US major also reached scale-up. Management calls the next 2-3 years a "very exciting opportunity" but warns the business cannot be analyzed quarterly.
• R32 is "juiced out" and still has legs: The new capacity is running above nameplate, export demand from the US and Europe is strong at equivalent or better pricing, and an additional ₹84 crore expansion is on track for February 2025.
• What to watch next quarter: Whether the promised demand uptick materializes by end-Q2, the commissioning of the ₹540 crore agro-specialty plant in September, and any further CDMO registration wins that convert the pipeline into visible revenue.

HPP: The Engine This Quarter

• 66% YoY growth driven by stable HFO operations and strong sales from the new R32 capacity, with both domestic and export order books healthy.
• R32 running hot: The plant is operating above nameplate capacity, described as "juiced out," with strong demand from the US and Europe at pricing equivalent to or better than India. An additional ₹84 crore capex to add 4,500 tonnes is on track for February 2025, and management expects to ramp it faster given the existing pipeline of inquiries.
• R22 pricing improving: Export market prices are showing signs of improvement and are expected to continue rising.
• HFO margins protected: A pass-through understanding with the customer ensures margins are completely insulated from input cost movements.
• HS, R22, R32 and HFO plants all operated at optimal capacity for another consecutive quarter.

Ganatra: "No, R32 is more than the capacity. So, we've had a very solid and strong response in the market on R32. It's ramped up to what you can, it's juiced out."

Specialty Chemicals: Destocking, Not Losing

• 30% YoY revenue decline driven by inventory rationalization at global agrochemical majors, which caused deferred purchasing decisions. The impact is mostly on volumes, with some pricing pressure, but management protects margins through alternative synthesis routes.
• Innovator insulation: A large part of the portfolio serves innovators under long-term supply contracts with top-five global companies and Japanese organizations. Pricing is structured on mutual cost agreements, so the current downturn is not expected to hit the bottom line.
• No wallet share loss to China: For key customers with firm arrangements, the phenomenon is purely deferral of buying decisions, not a shift to Chinese suppliers.
• Demand recovery signal: Management expects to see some uptick in demand at the end of Q2, with a more meaningful base business recovery in FY26. Demand scenarios should show recovery in the second half of FY25.
• New molecule at Surat: A new molecule for a global agro major was added with peak annual revenue potential of ₹40-50 crore over the next three years. A separate supply agreement for a patented agro product for the Japanese market adds ₹20-30 crore in incremental annual revenue from CY2025.

Kulkarni: "the pricing structure under which we have entered into understanding with them, it is not going to hit our bottomline and it will reflect the same numbers when it comes to EBITDA which are happening currently at Q1 or Q2 level"

CDMO: Pipeline Progress, Lumpy Revenue

• 13% YoY revenue decline, but management stresses this business cannot be analyzed on a quarterly basis. The focus is on improving order visibility, increasing the share of late-stage and commercial molecules, and deepening relationships with big pharma and biotech customers.
• Pipeline advancing: Work with a UK major pharma progressed from development to a scale-up order. A European major completed pre-validation, with the next stage expected in about six months. A US major pharma also completed development work and received a scale-up order.
• Drug application expansion: A European big pharma player's drug application was expanded in one therapeutic area, increasing optimism on initial peak annual revenue projections for that program.
• Bio Secure Act tailwind: CDMO pharma is seeing increasing RFPs from global majors looking to derisk portfolios away from China. The company is present in Europe, the US, and Japan for both agro and pharma CDMO.
• Registrations progressing: One molecule under an MSA is already registered; two more are expected later in the year. The eventual target is to secure one or two more MSAs over the coming years.
• FY27 aspiration: Management targets achieving the ₹10 crore aspiration by FY27, with extra capacity coming on stream at the end of CY2025, giving roughly a year to ramp from there.

Ganatra: "It's a service industry rather than a cost driven industry. You have got to make sure that you take the product, run the chemistry and provide it in time. That's the main part of the business."

Margins: Sequential Recovery Underway

• EBITDA margin dropped from 23.3% to 19.2% YoY, driven by exceptional ref gas pricing in Q1 last year, lower specialty sales, and a lower CDMO mix in the overall revenue basket. PAT fell 17%, reflecting higher depreciation from newly commissioned capex.
• Sequential improvement is the story: Margins have climbed from 15% in Q3 FY24 to 19.2% in Q1 FY25, and management remains on track to improve them gradually through the year.
• Overall EBITDA guidance: Management is guiding to 24-25% EBITDA, though this is described as a snapshot that will move as conditions evolve.
• NFASL gross margin dropped 400 bps QoQ due to the deferral of agchem orders; HFO performance remains strong. No pricing changes were made in either HFO or agchem.
• Interest costs declining QoQ and YoY, helped by an improved cash position, lower average working capital borrowing, renegotiated lender spreads, and inter-company borrowings offsetting at the consolidated level. Operating cash flow of ₹107 crore was aided by continuous working capital reduction.

Capex Pipeline: The Next Growth Leg

• ₹540 crore agro-specialty project: Targeted to commence commercial production by September 2024, with firm purchase orders already secured for the dedicated capacity in FY25. Peak revenues are still targeted for FY27, at roughly 1.1x the investment, and recent price deterioration has not impacted that peak number. The plant adds flexibility to run a different molecule if needed.
• AHF project (₹450 crore): Enhancing HF capacity by 40,000 metric tonnes at Dahej, on track to commence by end-FY25 or early-FY26. Internal consumption will absorb much of the output; merchant sales are expected at about 7,000-8,000 metric tonnes. Downstream applications for semiconductors and advanced materials will take time to mature.
• cGMP-4 Phase 1 (₹288 crore): Progressing to plan for commissioning by end of CY2025, adding CDMO capacity that underpins the FY27 aspiration.
• Surat new capability (₹30 crore): To be commissioned in Q2 FY25, with incremental revenue starting the following quarter.
• Next growth capex: Management expects to begin formulating views by the middle of CY2025, while ensuring balance sheet strength and net debt to equity stay within guidance.

Ganatra: "So, again, you do an HF plant in this business to stay in business."

Guidance & Commitments

Key Metrics